Semaglutide clinical outcomes
The most consequential results here count serious illness. Those findings deserve room of their own before the question of longevity returns.
Event trials
In SELECT, involving 17,604 adults with established cardiovascular disease and overweight or obesity but no diabetes, semaglutide reduced the combined outcome of cardiovascular death, nonfatal myocardial infarction and nonfatal stroke versus placebo. The reported hazard ratio was 0.80, with a 95% confidence interval of 0.72-0.90.
The FLOW trial enrolled 3,533 people with type 2 diabetes and chronic kidney disease. Its primary combined outcome included kidney failure, a decline in estimated kidney filtration of at least 50%, and kidney-related or cardiovascular death. The hazard ratio was 0.76, with a 95% confidence interval of 0.66-0.88.
A hazard ratio compares the rate of events over follow-up between groups. I attach the event definitions to those figures: a combined result does not establish that every component changed by the same amount.
These trials demonstrate clinical benefit in people with substantial existing risks. I put that well ahead of a speculative rejuvenation claim. They still leave a different question unanswered: whether healthy people generally gain years of life.
The weight comparisons
In STEP 1, adults with overweight or obesity without diabetes were followed to week 68. Mean body-weight change from baseline was -14.9% with semaglutide and -2.4% with placebo. This is a result measured during the trial's treatment period.
The 72-week comparison with tirzepatide in adults with obesity found greater average weight loss with tirzepatide: -20.2%, compared with -13.7% for semaglutide. The size of those weight changes leaves the question of a universal winner open. That comparison asked about weight in its participants; the separate cardiovascular and kidney trials asked other questions.
For staying power, I want both the change during observation and an account of what follows withdrawal. The STEP 1 weight figure quoted here answers the first. The tesamorelin withdrawal result cannot fill in the answer for semaglutide simply because both medicines changed body composition.
A scale reading can be substantial and still leave a maintenance question. The study-window comparison makes the different observation periods visible.
Appetite and prescription uses
Semaglutide copies GLP-1, a gut hormone involved in fullness and blood-sugar control. It promotes insulin release when glucose is elevated, suppresses glucagon, slows gastric emptying and acts on appetite pathways. Eating less is central to its weight effect.
I favor the account of appetite over language about simply “burning” weight away. Appetite and digestion are part of the process, which also helps explain why the adverse-effect discussion is so often about the stomach and bowel.
Approved semaglutide uses include type 2 diabetes, chronic weight management, cardiovascular risk reduction in adults with established cardiovascular disease and overweight or obesity, and fatty liver disease with inflammation and scarring. The approved use depends on the formulation and population. These are prescription indications; general life extension has not been established.
Compounded preparations are not FDA-approved, and evidence for the manufactured medicine cannot establish their ingredients, strength or manufacturing quality.
Symptoms, cautions, experiences
The semaglutide safety review describes mostly mild-to-moderate, transient gastrointestinal effects and increased biliary disease, including gallstones. Low counts of pancreatic and thyroid cancers left their signals unresolved. Diabetic retinopathy complications were increased in a trial, particularly with rapid improvement in blood sugar.
The thyroid C-cell tumor warning comes from rodent findings; a clear human cancer increase has not been established. A personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2 is a contraindication. Pancreatitis is a class warning. These cautions require the actual medical context, even alongside favorable trial outcomes.
Community accounts describe quieter thoughts about food, reduced cravings, weight loss and improved blood-sugar readings. They also describe nausea, bowel changes, burping, reflux, fatigue, food aversion, hair shedding, dizziness and soreness at injection sites. These are anecdotal accounts, unverified as causes and not clinical evidence of benefit or harm. They establish neither frequency nor a treatment timetable.
I understand the immediacy of an account about less preoccupation with food. A hazard ratio feels more remote. Both deserve accurate names. The personal accounts describe experience; the controlled trials test comparisons. Neither permits this site to decide a person's treatment.